Purpose To investigate whether androgen conversion rates after supplementation with dehydroepiandrosterone (DHEA) differ, and whether differences between patients with diminished ovarian reserve (DOR) are predictive of pregnancy chances in association with in vitro fertilization (IVF).
Introduction
While androgen effects on follicle maturation in humans have remained controversial [1] , experiments in rodents strongly support an essential androgen function, mediated by the androgen receptor (AR) on granulosa cells, especially at early stages of follicle maturation, up to preantral stages [2] . Direct studies of androgen effects on human follicle maturation do not exist. Androgens, indeed, for the longest time, have been considered detrimental to normal follicle maturation [1] . Similarities of receptor expression in mouse and human follicles, however, suggest that small growing human follicles may be as much androgen-dependent as mouse follicles [1] . Such a conclusion is also supported by clinical evidence: Supplementation with dehydroepiandrosterone (DHEA), in women with objectively determined DOR improves IVF cycle outcomes and pregnancy chances in general (reviewed in reference 3). These investigations were initiated after a 43-year-old patient with severe DOR developed a typical polycystic ovary (PCO) phenotype over consecutive in vitro fertilization (IVF) cycles after self-medicating with DHEA [3] . DHEA has been utilized to induce PCO-like ovarian phenotypes in rats [4] , and mice [5] . From subsequent observational studies we then concluded that DHEA significantly and beneficially affects functional ovarian reserve (FOR), egg and embryo quality and overall pregnancy chances in women with DOR [6] . How DHEA supplementation causes these effects has, however, remained undetermined.
In women DHEA in a majority converts to testosterone (T), and to a lesser degree to estradiol [7] . The hormone, therefore, can affect processes through AR or estrogen receptors [1] . That a minimum of 6 weeks of DHEA supplementation are required to see significant beneficial effects [6, 8] , supports a DHEA effect on relatively early follicle maturation stages, coinciding with presence of ARs, likely only present at small growing follicle stages, up to early preantral follicles [1] . Beneficially affected follicles, therefore, still will require weeks to months to reach gonadotropin-sensitive stages, where they become clinically relevant, explaining the need for at least 6 weeks of supplementation prior to IVF cycle starts [6, 8] . During this time period DHEA conversion dynamics into other androgens offer a potential model to investigate androgen effects on follicle maturation.
We recently reported preliminary clinical data, suggesting that T levels after DHEA supplementation are statistically associated with IVF pregnancy chances [9] . Increasing androgen levels have previously been associated with increasing AMH levels, and, therefore, better FOR [10, 11] . Better androgen levels have also been associated with higher IVF pregnancy chances [12] , though data have remained conflicted [13] .
Ovarian genotypes and sub-genotypes of the fragile X mental retardation 1 gene (FMR1) have recently been demonstrated to affect ovarian aging [14] and IVF pregnancy chances [15] . They differ from classical expansive FMR1 genotypes of premutation and mutation ranges, traditionally used to predict neuro-psychiatric risks, including the fragile X syndrome. Because of their effects on female reproduction, we suggested that fertility studies should now be stratified for these FMR1 genotypes and sub-genotypes [16] . This was done in this study.
Here presented study offers a systemic investigation of androgen effects on IVF and, by doing so, offers insights into the pathophysiology of DOR, androgen effects on pregnancy chances, differences at younger and older ages and of FMR1 effects. Here presented data also offer evidence for the importance of androgens to normal follicle maturation and female fertility in humans.
Materials and methods

Patients
This study involves a cohort of 213 women with primary or secondary infertility and a diagnosis of DOR. A DOR diagnosis was reached based on abnormal FSH [17] and/or AMH levels [18] , outside of the 95 % confidence interval (CI) for age and/or because of age above 40 years [19] . To prevent confounding biases from repeat cycles, only first IVF cycles, which offered a complete data set as described below, were included.
Androgen supplementation DOR patients at our center, prior to IVF cycle start, are for at least 6 weeks routinely supplemented with 25 mg of micronized pharmaceutical grade DHEA, p. o., TID [6] .
Assessments of androgen levels
Androgen profiles, including DHEA, DHEA-sulfate (DHEAS), total T (TT) and free T (FT) were serially evaluated monthly, at DHEA supplementation start (i.e., "baseline"), tagged with the subscript " BL ", and at IVF cycle start, with subscript " CS ". All androgens were measured by routine commercial assays.
Ovarian stimulation for IVF
With first menses, after at least 6 weeks of DHEA supplementation, women with DOR were started in a microdose agonist ovarian stimulation cycle (leuprolide acetate, 50 μg, s.c., BID, Lupron®, Abbot Laboratories, North Chicago, Illinois), with daily gonadotropin dosage of 450-600 IU, all FSH but 150 IU, given as human menopausal gonadotropin (hMG) (gonadotropin manufacturers varied, based on patient preference/insurance). In DOR patients our center performs oocyte retrieval whenever at least one mature follicle of ≥20 mm mean diameter is seen on ultrasound.
Definition of clinical pregnancy
A pregnancy was defined as clinical if at least one gestational sac and fetal heartbeat were confirmed on vaginal ultrasound.
FMR1 genotypes and sub-genotypes
FMR1 genotypes and sub-genotypes are based on a normal range of 26 to 34 (median 30) CGG triple nucleotides (CGG n0 26-34 ). Women with both alleles in normal range are considered to have a normal genotype (norm), those with one outside range as heterozygous (het) and those with both alleles outside range as homozygous (hom). Het and hom genotypes, depending on whether abnormal alleles are above (high) or below (low) normal range, can then be further subdivided into sub-genotypes [14] [15] [16] .
Statistical analyses
Where appropriate, statistical analyses were carried out by using Mann-Whitney U tests, t-tests or ANOVAs. All post hoc procedures utilized the Holm-Sidak test but were confirmed with independent t-tests for significance. Differences in distributions between categorical data were compared using Chi-Square tests. All tests were 2-tailed, with P<0.05 considered statistically significant.
A series of logistic regressions was performed to determine whether various androgen levels affected clinical potential for pregnancy in association with IVF. In interactions between two contributing factors the effect of the response variable depends on the value of the other factor. For multi-factor ANOVAs interaction terms of α were set at 0.05 in regards to individual contributions (at α ≤0.05 the 95 % CI indicates that factors of interaction terms are significant) but at 0.10 for interaction terms.
The first series of logistic regression models were adjusted (in weeks) for duration of DHEA supplementation from DHEA start ( BL ) to IVF cycle start ( CS ). When examining changes in various androgen levels, models were adjusted (in weeks) for time intervals between blood draw BL and blood draw CS . To correctly assess potential effects of androgens and potential effects of the inter-conversions between androgens on pregnancy odds, models were, where indicated, further adjusted for length of DHEA supplementation, oocyte yields and patient age. (Pearson product moment correlation coefficients confirmed that there were significant negative correlations between age and DHEA CS , r00.274, P≤0.001; age and TT CS , r 00.291, P 00.002; age and FT CS , r 00.381, P≤0.001; and age and oocyte yields, r00.258, P≤0.001. There was also a significant positive correlation between oocyte yields and FT CS , r00.204, P00.035.)
To correctly assess the differences between low, normal and high DHEA levels at cycle start, DHEA BL and DHEA CS were binned, and re-coded into categorical variables. To determine whether there was change from androgen BL to androgen CS , the same grouping paradigm was used at both time points. To offer a fair comparison, optimal cut offs were calculated, based on percentiles to yield equal sample sizes. Low, normal and high groups were assessed independently to examine the effects of androgens BL and androgens CS on pregnancy odds. They were for DHEA BL and DHEA CS , respectively: for low DHEA levels: <461 ng/dL (n BL 0113 , n CS 0 7 0 ) ; f o r n o r m a l 4 6 1 -6 6 1 n g / d L ( n B L 04 5 , n CS 069); and for high >661 ng/dL (n BL 045, n CS 069). Five patients missed cycle DHEA data but did have DHEAS data.
To assess pregnancy odds, factor increases or decreases in pregnancy odds were calculated as e β for increases and 1/e β for decreases, using the β coefficients derived from the logistic regression. To directly assess an androgen conversion index from DHEA to T, we created the following formula: Ratio 0 % change T/absolute value of % change in DHEA. The actual formula is:
The same formula is potentially applicable to conversion calculations for any androgen. This is a unit-less formula because a unit of DHEA is not necessarily converted into a unit of T (i.e., the molar ratio of DHEA to T is not 1:1).
Institutional review board (IRB)
Here presented data only involved the retrospective review of an anonymized electronic research database. Such studies at our center only require expedited IRB reviews since patients at initial consultation are asked to sign a universal informed consent, which allows for medical record reviews for research purposes if the patient's medical record remains confidential and her identity protected. These conditions were met, and the study, therefore, underwent only expedited review. Patients also signed a specific consent for FMR1 testing. The center's clinical and research staffs are, in accordance with federal HIPAA rules, in writing committed to confidentiality of medical records and privacy of individual patients. Figure 1a demonstrates a significant difference between pregnant (M01.30, SD02.25) and non-pregnant groups (M00.33, SD00.86; P00.015), which, independently, was primarily observed amongst younger women (pregnant, M02.96, SD03.01; not pregnant, M01.05, SD01.44; P 00.007), favoring better conversion in women who achieved pregnancy. Amongst pregnant patients, there was also a significant difference between younger women with better conversions (M02.96, SD03.01) and older women with lower conversion rates (M00.31, SD00.69; P<0.001). Figure 1b demonstrates that the conversion rates from DHEA to FT significantly differed between FMR1 genotypes and sub-genotypes [F (3, 54)03.52, P00.021) and between younger and older patients [F(1, 54) 09.55, P00.003]. The interaction term between FMR1 genotypes/sub-genotypes and age also almost reached significance (P00.057).
Results
A post-hoc comparison (Holm-Sidack method) confirmed significant differences in conversion rates between het-norm/high (M 01.38, SD 02.60) and het-norm/low FMR1 sub-genotypes (M00.01, SD00.64; P00.003), with the former converting more efficiently than the latter; and between younger (M02.01, SD02.46) and older patients (M00.24, SD00.70; P00.003).
FSH BL and AMH BL comparison with FSH CS and AMH CS , and FSH/androgen and AMH/androgen ratios FSH BL and AMH BL differed significantly between pregnant and non-pregnant patients (both P<0.001), but with cycle start only AMH CS had improved (P < 0.001) (Fig. 2a) . Comparing androgens at baseline with androgens at cycle start, only FT CS was significantly increased, comparing pregnant and non-pregnant women (P00.006) (Fig. 2b) .
Since, especially at small follicle sizes, FSH and androgens are believed to act synergistically [20] , we investigated ratios of FSH over the various androgens. Significant differences were noted between pregnant and non-pregnant women in: FSH BL /DHEA BL (P00.039), FSH BL /DHEAS BL (P0 0.040), FSH BL /DHEA CS (P 00.013), FSH BL /DHEAS CS (P00.009) and FSH BL /FT CS (P00.014). FSH BL /TT CS almost reached significance (P00.051) ( Fig. 2C1 and C2 ). Analyses of FSH CS over cycle start androgen levels, proved all not significant (data not shown).
Similarly, the following AMH/androgen ratios were found to differ between pregnant and non-pregnant women: AMH BL / DHEA BL (P < 0.001), AMH BL /DHEAS BL (P 00.002), AMH BL /DHEA CS (P<0.001) and AMH BL /DHEAS CS (P0 0.002). AMH BL /TT CS (P00.005). In contrast to FSH CS , which had not shown significant ratios, AMH CS did demonstrate one significant ratio, AMH CS /DHEAS CS (P00.038) (Fig. 2d) .
A series of logistic regressions, adjusting for age eliminated significance in all previously significant ratios, except for AMH CS /DHEAS CS (β0−0.499, SE00.240, P00.048). For every unit increase in ratio, clinical pregnancy potential decreased by a factor of 1.7.
Evaluation of pregnancy chances per DHEA, binned low, normal or high Assessments of pregnancy chances, based on binned DHEA BL (or other androgens) did not affect pregnancy chances, either based on low, normal or high DHEA levels or based on FMR1 genotypes and sub-genotypes (data not shown).
DHEA CS , however, did: In presence of low DHEA CS , odds of achieving pregnancy were significantly influenced by FT CS (β00.948, SE±0.361, P00.009), increasing pregnancy odds 2.6-fold. In presence of normal DHEA CS levels, FT CS missed significance (β00.456, SE±0.255, P00.074). With high DHEA CS levels, odds of achieving clinical pregnancy were significantly influenced only by DHEAS CS (β0 0.607, SE± 0.193, P 00.002), increasing odds 1.8-fold (Fig. 3a) . With normal levels of DHEA CS , change of FT BL to FT CS was almost significant in affecting pregnancy chances (β 01.662, SE ± 0.858, P 00.053). With high DHEA CS , the ratio of DHEAS CS /DHEA CS also significantly affected pregnancy chances (β00.040, SE± 0.014, P 00.005) (Fig. 3b) , increasing pregnancy odds 1.04-fold.
After adjusting for age, oocyte yields and length of DHEA treatment (time between DHEA BL and DHEA CS ), FT CS was, in presence of low DHEA CS , significantly associated with increased odds of pregnancy (β00.882, SE±0.401, P00.028) by a factor of 2.4. In presence of high DHEA CS , increasing DHEAS CS (β 00.568, SE ± 0.196, P00.004) and the ratio of DHEAS CS /DHEA CS (β00.040, SE±0.015, P00.006) also increased odds of pregnancy by factors of 1.8 and 1.04, respectively (Fig. 3c) . Pregnancy chances based on FMR1 genotypes and sub-genotypes
As Fig. 4a demonstrates, in women with het-norm/high FMR1 sub-genotype, TT CS was associated with greater odds of achieving pregnancy (β00.106, SE±0.052, P00.043), increasing pregnancy odds, though only 1.1-fold. In contrast, norm and het-norm/low women demonstrated only a trend towards significance (data not shown). Even collapsed hom patients were too few in number to allow for valid statistical analyses. FT CS almost reached significance in increasing odds of pregnancy in women with het-norm/low sub-genotype (β00.502, SE±0.267, P00.060), and a similar trend was observed in norm and hetnorm/high women (data not shown). Moreover, in het-norm/low patients, interaction between DHEA CS and FT CS actually decreased odds of clinical pregnancy 1.3-fold (β0−0.295, SE±0.155, P00.056). Adjusted for oocyte yields, patient age, and time between DHEA BL and DHEA CS , the interaction between DHEA CS and FT CS significantly affected clinical pregnancy chances in women with het-norm/low FMR1 sub-genotypes (β00.333, SE±0.180, P00.064), actually decreasing odds of pregnancy 1.4-fold (Fig. 4b) . A similar trend, not reaching significance was also observed for het-norm/high but not for women with norm genotypes (data not shown). Norm women, however, demonstrated almost statistically significant odds of increased pregnancy rates based on changes from DHEAS BL to DHEAS CS (β00.206, SE±0.111, P00.062) (Fig. 4b) .
Androgens in FMR1 genotypes and sub-genotypes, stratified by age In younger women (≤38 years), TT significantly changed between TT BL and TT CS assessments for the various FMR1 genotypes and sub-genotypes [F (2,10)05.53, P00.024]. Post-hoc comparisons (Holm-Sidak test) suggested the mean TT change to be significantly lower for het-norm/ low (M 0−116.69, SD 0152.29) than for het-norm/high FMR1 sub-genotypes (M028.00, SD 057.98; P00.028) and norm genotypes (M026.38, SD 025.59; P00.009) (Fig. 5a ). As the figure suggests, het-norm/low women at younger ages demonstrate higher mean TT BL than TT CS .
None of the mean ratio values between androgens showed significant differences for different FMR1 genotypes and sub-genotypes between baseline and cycle start. Fig. 1 Androgen conversion rates by age and FMR1 genotypes and sub-genotypes. Two-way ANOVA for pregnancy outcome and age group demonstrated significant interaction (P00.025). a There was also a significant interaction between pregnant and non-pregnant women (P00.015), independently observed in younger women only (P00.007). Amongst pregnant women, older women also demonstrated a significantly lower androgen conversion rate from DHEA to T (P<0.001). b demonstrates that androgen conversion rates differ significantly between FMR1 genotypes and sub-genotypes (P00.021), between younger and older patients (P00.003), and in the interaction term between FMR1 and age (P00.057). *Post-hoc comparison (HolmSidack) demonstrated that subgenotype het-norm/high converts androgens significantly more efficiently than het-norm/ low (P00.003), and younger convert androgens more efficiently than older women (P00.003) Moreover, older women also demonstrated significant differences in androgen ratios: Specifically, DHEAS CS / DHEA CS differed between FMR1 genotypes and subgenotypes [F(3,164)03.22; P00.024]. Holm-Sidak posthoc test suggests that mean DHEAS CS /DHEA CS for women with hom genotype (M0126.4, SD0126.2) was significantly higher than in women with het-norm/high (M063.5 %, SD0 39.6; P00.003) and het-norm/low FMR1 sub-genotypes (M069,4 %, SD042.7; P00.005) and with norm genotype (M076.8 %, SD047.5; P00.013) (Fig. 5c) . As the figure demonstrates, this may suggest lower DHEA CS in women with hom genotypes.
The change between DHEAS BL and DHEAS CS , in itself, indeed occurred significantly differently between FMR1 genotypes and sub-genotypes [F(3,165)02.98; P00.033). Holm-Sidak indicates that in hom women the increase in mean levels from DHEAS BL to DHEAS CS was significantly larger (M0330.71, SD0382.85) than in either het-norm/ high (M057.49, SD0210.99; P00.003) or norm women (M0103.76, SD0209.53; P00.009). 4 Pregnancy chances based on FMR1 genotypes and subgenotypes. Predicted probabilities of pregnancy odds are presented as means and 1 SE of the mean. a demonstrates that increasing TT CS in women with het-norm/high FMR1 sub-genotype was associated with greater odds of pregnancy (P00.043). The collapsed hom genotype, overall, behaved differently from other FMR1 genotypes/sub-genotypes: Predicted probabilities for pregnant and non-pregnant groups in hom women were very similar, while other genotype and subgenotypes demonstrated statistical trends. Rising FT CS also almost reached significance in het-norm/low (P00.060) and so, though to lesser degree, did other genotypes and sub-genotypes. As b demonstrates, in het-norm/low sub-genotypes, interaction between DHEA CS and FT CS decreased odds of pregnancy (P00.056) and this conclusion remained valid after adjustments for oocyte numbers, age and length of DHEA supplementation (P00.064). Het-norm-high demonstrated a similar trend but not women with norm and hom genotype. Odds of pregnancy, however, did demonstrate a trend in norm women, based on ΔDHEAS BL to DHEAS CS (P00.062)
Discussion
Androgen conversion rates by age and FMR1
Women who conceived had better conversion rates than those who did not, and this was particularly apparent amongst younger patients (Fig. 1a) . These observations are of significance because they suggest that: (a) better conversion from DHEA to T improves pregnancy chances in women with DOR; (b) younger women convert androgen more effectively than older women; (c) that older women may, therefore, potentially benefit from more direct T administration and (d) that the evaluation of androgen levels in women with DOR is beneficial. FMR1 genotypes and sub-genotypes stratified by age. a demonstrates that in women ≤38 years Δ TT BL to TT CS FMR1 genotypes and sub-genotypes, overall significantly changed (P00.024). Post-hoc comparisons further demonstrated that this change in Δ of mean TT was significantly smaller for het-norm/low than het-norm/high (P0 0.028) or norm (P00.009) but mean ratio values between androgens did not differ. As b demonstrates, older women > age 38 behaved differently: DHEAS CS differed significantly between FMR1 genotypes and sub-genotypes (P00.026), and post-hoc analysis confirmed that DHEAS CS was significantly higher in hom than het-norm/high (P0 0.003) and het-norm/low women (P00.005). Older women, however, also demonstrated significant differences in mean androgen ratios: c demonstrates that DHEAS CS /DHEA CS differed significantly between FMR1 genotypes and sub-genotypes (P00.024), and post-hoc analysis suggested that hom women had a significantly higher ratio than hetnorm/high (P00.003), het-norm/low (P00.005) and norm women (P0 0.013) Not shown in our result section is that we attempted by receiver operating curve (ROC) to determine whether, at least in younger women, below age 38 years, androgen conversion rates cold be predictive of pregnancy outcome. Likely due to small patient sample size, we were, however, unable to demonstrate significance (area under the curve 0.694, 95%CI 0.369-1.000; P00.262)
Conversion from DHEA to FT significantly differed between FMR1 genotypes and sub-genotypes (Fig. 1b) , and the interaction term between FMR1 and age barely missed significance (P00.057). These observations support that, as previously reported [15, 16] , variations in pregnancy rates between FMR1 genotypes and sub-genotypes in populations with better FOR would, be more apparent. This is also supported by the post-hoc analysis, demonstrating that, independent of age, het-norm/high sub-genotypes converted androgens significantly better than het-norm/low women, as did younger in comparison to older women.
Combined, these data point towards improved pregnancy chances for women who most efficiently convert DHEA to T. The data, however, also point towards differences in efficiency of conversion, based on FMR1 genotypes and sub-genotypes.
FSH BL/CS , AMH BL/CS , FSH/androgen and AMH/androgen ratios
This study also demonstrated that FSH BL was lower and AMH BS higher in patients who conceived (Table 1) . Lower FSH and higher AMH, of course, denote better FOR and, therefore, better pregnancy chances are expected [17, 18] . By IVF cycle start, however, only AMH was left significantly associated with pregnancy chances (Fig. 2a) , which correlates well with the earlier reported observations that AMH, but not FSH improves with DHEA supplementation, and that increases in AMH levels are associated with improved pregnancy chances with IVF [21] .
Comparing androgen levels at baseline and cycle start between pregnant and non-pregnant women, only FT CS differed significantly, demonstrating a significant increase from FT BL in pregnant women (P00.006; Fig. 2b ). This observation, of course, supports that efficient DHEA to FT conversion is beneficial for pregnancy chances.
Considering previously noted synergism between androgens and FSH [19, 22] , and likely negative feedback of AMH on small growing follicles [23] , we also attempted to investigate any possible interplay between androgens and FSH and androgens and AMH. Our hypothesis was that synergisms/antagonisms between FSH/AMH and androgens might be detectable by investigating FSH/androgen and AMH/androgen ratios. Neither had ever before been investigated, and since we presumed such interactions to occur at small growing follicle stages, we expected them to become more "visible" at baseline rather than at IVF cycle start.
Results, indeed, confirmed this by demonstrating significant differences in pregnancy chances based on the following FSH BL /androgen ratios: FSH BL over DHEA BL , DHEAS BL , DHEA CS , DHEAS CS and FT CS . It barely missed significance with FSH BL /TT CS (P00.051) (Fig. 2C1 and C2 ). In contrast, FSH CS ratios did not demonstrate any significant associations. This dichotomy of results is supportive of our hypothesis that androgen/FSH ratios at baseline may accurately reflect the small growing follicle pool, representing most of FOR [1] . AMH/androgen ratios further strengthen this concept. With only one exception, all pregnancy-associated AMH/androgen ratios related to AMH BL , Those included ratios with DHEA BL , DHEAS BL , DHEA CS , DHEAS CS and TT CS . Only AMH CS /DHEAS CS related to AMH CS (Fig. 2D1 and D2) .
FSH/androgen and AMH/androgen ratios, thus, appear to offer new, and quite direct assessments of the small growing follicle pool, representing true FOR. Currently, AMH is considered to best reflect this stage of follicle maturation [24] . Here presented data suggest that androgen/FSH and androgen/AMH ratios at baseline may have prognostic significance that warrants further investigation. These ratios, further, raise possible therapeutic benefits: For example, adjustments in androgen supplementation, based on FSH and/or AMH levels, may make it possible to bring ratios into, yet to be determined, therapeutic ranges.
Remarkably, only AMH CS /DHEAS CS maintained significance after adjustment for patient age. This confirms the importance of age in predicting IVF success but also points to the possibility that the AMH CS /DHEAS CS ratio may, independent of age, predict IVF pregnancy chances. Like all FOR assessment tools, AMH levels, in principle, are age-specific [18] . At 1.05 ng/mL, AMH, however, independent of age, has been reported in DOR to differentiate between better and poorer IVF pregnancy chances [24] , and, in comparison to FSH, may, therefore, be more reflective of age-independent characteristics of FOR, required for pregnancy success. These data, ultimately suggest that, aside from the AMH CS / DHEAS CS ratio, all other here reported desirable ratios, likely, will have to be established in age-specific ways.
DHEA and other androgens binned for low, normal and high levels DHEA BL , and other androgens at baseline did not affect overall pregnancy chances or in association with individual FMR1 genotypes or sub-genotypes. In contrast, DHEA CS did: If DHEA CS was low, increasing FT CS improved odds of pregnancy (Fig. 3a) . As DHEA CS improved towards normal, FT CS slowly lost significance (P00.074), with high DHEA CS levels no longer showing any association with FT FS , and odds of achieving pregnancy only affected by rising DHEAS CS .
This again points towards the importance of effective DHEA conversion to T but, likely, only if androgens are initially low.
As baseline androgens increase, importance of further androgen conversion declines, suggesting the possibility of a therapeutic androgen range for maximal pregnancy chances. That at normal DHEA CS levels changes of FT BL to FT CS only almost reached significance (P00.053) and that at high levels of DHEA CS , once again, only the DHEAS CS /DHEA CS ratio significantly affected pregnancy chances (Fig. 3b ) also support such an interpretation. It is further supported by the observation that after adjustments for length of DHEA supplementation, female age and oocyte yields, in presence of low DHEA CS , FT CS , still, was significantly associated with increasing pregnancy odds, and in presence of high levels of DHEA CS , only increasing DHEAS CS and the DHEAS CS /DHEA CS ratio were positively affecting pregnancy chances (Fig. 3c) .
The data, therefore, also suggest that in women who poorly convert DHEA to T, the bottleneck in sequential conversions appears to lie at the conversion of [DHEA ↔ DHEAS] to androstenedione. So identified patients may, therefore, benefit from direct administration of T rather than DHEA.
FMR1 genotypes and sub-genotypes
FMR1 genotypes and sub-genotypes appear to reflect different degrees of androgen effectiveness, as TT CS in het-norm/ high women was significantly associated with greater odds of pregnancy (P00.043), and in norm and het-norm/low patients only suggested a trend towards significance (Fig. 4a) . Similarly, FT CS almost reached significance for het-norm/low and demonstrated trends for norm and het-norm/high.
Interaction between DHEA CS and FT CS in het-norm/low patients decreased odds of pregnancy (P00.056). However, most importantly, after adjustment for length of DHEA supplementation, female age and oocyte yields, the interaction between DHEA CS and FT CS still significantly affected pregnancy chances for women with het-norm/low sub-genotype; but only trends were observed with het-norm/high and norm (Fig. 4b) . Least affected by conversion from DHEA CS to FT CS appeared to be women with norm genotypes but they, interestingly, demonstrated almost statistically significant odds of increased pregnancy rates (P00.062) based on changes in the DHEAS BL to DHEAS CS ratio, suggesting that in these patients androgen conversion rates may differ from other FMR1 genotypes (Fig. 4b) , and higher T levels may be less important.
FMR1 genotypes and sub-genotypes and age
Stratification by age is important because it allows insights into two distinct forms of DOR, so-called premature ovarian aging (POA) in younger women, and physiologic aging with advanced female ages [17, 19] . Such stratification, once more, demonstrates differences in androgen conversion: young women (≤38 years) demonstrated significant differences in progression from TT BL to TT CS . Specifically, women with het-norm/low sub-genotypes demonstrated significantly slower increases in TT between these two time points than het-norm/high and norm patients (Fig. 5a ). These data, therefore, suggest distinct differences in how FMR1 genotypes and sub-genotypes process androgens at different ages.
Women with het-norm/low sub-genotypes have been reported to demonstrate significantly reduced pregnancy chances with IVF [15, 16] . Considering the poor androgen conversion rates observed in this study in het-norm/low women, lower pregnancy chances with this FMR1 subgenotypes should, therefore, not surprise.
While young women demonstrated no differences in mean androgen levels between FMR1 genotypes and subgenotypes, older women demonstrated distinct differences in DHEAS CS . Specifically, collapsed hom patients demonstrated significantly elevated DHEAS CS in comparison to both het sub-genotypes (Fig. 5b ) and higher DHEAS CS / DHEA CS ratios than het sub-genotypes and norm patients (Fig. 5c) . Moreover, hom patients increased mean levels of DHEAS BL to DHEAS CS to a significantly larger degree than het-norm/high and norm women (Fig. 5d) .
Based on their FMR1 genotype and sub-genotype, younger and older women with DOR, thus, appear to convert androgens at different rates. FOR differs in young oocyte donors, depending on race. At somewhat older ages the differences have, however, already significantly diminished in women with infertility [25] . At least partially, FOR differences observed between races are due to varying FMR1 genotype distributions, with African women demonstrating disproportionally more het-norm/low sub-genotypes and Asian women more het-norm/high [16] . IVF outcome differences between races, partially attributed to such variations in FMR1 genotype distributions [25] , may, therefore, ultimately, reflect differences in androgen processing.
The increased importance of DHEAS CS /DHEA CS ratio in older women suggests that, lacking ability to convert [DHEA ↔ DHEAS] to T as well as younger women, they accumulate DHEAS. High DHEAS CS /DHEA CS ratios, independent of age, therefore, likely, suggest a poorer pregnancy prognosis. Younger women with poor androgen conversion, and older women in general may, therefore, benefit from direct T supplementation in place of or in addition to DHEA.
Here presented data offer also a first glimpse at the possible function of the hom genotype of FMR1. While functions of norm and het genotypes have previously been well defined [14] [15] [16] , hom, because it is comparatively rare, is not well understood. Based on higher DHEAS CS , this study suggests that hom women convert androgens poorer than either norm or het females. Hom patients, therefore, can be expected to demonstrate poorer responses to DHEA supplementation, and poorer clinical outcomes with IVF, though that remains to be confirmed by clinical studies.
Summary and conclusions
The evolving picture, therefore, suggests that younger women convert androgens better than older women, though how well androgens are converted appears to differ between FMR1 genotypes and sub-genotypes at younger as well as older ages, though with greater impact at younger ages. Better IVF pregnancy rates after DHEA supplementation in younger than older women support this observation [8] .
Whether androgens are beneficial for normal follicle maturation and female fertility has in humans remained controversial [1] . Indeed, only recently, did two commentaries suggest that DHEA supplementation in women with DOR should not be considered [26, 27] . So far only one, underpowered clinical trial of DHEA supplementation has been reported [28] , and most reported studies utilized lower power of evidence [6] . Lack of recruitment resulted in the abandonment of at least two prospectively randomized studies of DHEA in the U.S. and Europe, in which our center was involved (Government ID# NCT00419913). Two trials are still underway but recruitment is excruciatingly slow (Government ID# NCT00948857 and #NCY00650754), as, perceiving themselves "out of time," DOR patients are difficult to recruit into randomizations to placebo.
It recently occurred to us that the investigation of androgen conversion rates after DHEA supplementation might improve our understanding of DHEA effects on ovaries. Like in the mouse, in humans granulosa cells of small growing follicles demonstrate AR, FSHR and AMHR [1] . Synergistic activity on granulosa cells between androgens and FSH at these stages appears likely [20, 22] . Effects of AMH are less well understood. Kristensen et al. recently reported that peripheral AMH correlates with peripheral androgens [11] . Androgens, FSH and AMH, through their interaction, likely, affect follicle recruitment and small follicle growth, androgens and FSH synergistically, and AMH inhibitory. In high recruitment situations, like polycystic ovarian syndrome (PCOS), AMH, therefore, is high, and in low recruitment environments, like hormonal contraception, pregnancy and DOR, AMH is low [25] . Genotypes and sub-genotypes of the FMR1 gene also appear to influence follicle recruitment, and are closely associated with ovarian aging patterns [14, 15] . That they vary in androgen conversion rates may offer a potential physiological link between these observations. This study investigated a unique patient population of 213 DHEA-supplemented infertile women with DOR. All, because of a DOR diagnosis, had undergone FMR1 evaluations and had a complete set of baseline androgen data at DHEA supplementation start and, after at least 6 weeks of DHEA supplementation, at IVF cycle start. Finally, all patients completed a first IVF cycle, allowing for detailed outcomes assessments.
In such an unfavorable population the observed clinical pregnancy rate (positive fetal heart on ultrasound) of 22.1% is noteworthy, with women under age 38 actually conceiving in 34.1% of cycles. That pregnancy rates did not differ based on FMR1, may on first glance surprise since we previously reported that het-norm/low women experience significantly lower pregnancy rates than women with norm FMR1 genotype [15] . Those data were, however, generated in women with better FOR. Here presented data suggest that, once ovarian reserve is significantly compromised, ovarian FMR1 genotypes and subgenotypes no longer matter to the same degree. This interpretation of results is also supported by the observation that FORs in young donors vary significantly based on FMR1; but in older infertility patients differences have largely disappeared [29] .
DOR appears to represent an androgen deficient state, whether in younger or older women. To what degree, is currently under investigation at our center. Since androgens mostly derive from adrenal precursors, DOR, at least in part, has to reflect a clinical insufficiency state of the adrenal zona reticularis. DOR, therefore, mirrors in opposing features the hyperandrogenism of PCOS, for decades recognized as adrenal and ovarian in etiology.
FSH and AMH/androgen ratios are, to a rather surprising degree, predictive of pregnancy success. One can hypothesize that these ratios may better represent the small growing follicle pool than either FSH or AMH alone. They also offer potential therapeutic benefits by allowing for the individualization of androgen dosages, based on FSH and AMH levels, and, therefore, for diagnostic and therapeutic reasons deserve further investigations.
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